Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H20N2O3 |
Molecular Weight | 264.3202 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CC(=O)OC1=CC=C(NC(C)=O)C=C1
InChI
InChIKey=QTGAJCQTLIRCFL-UHFFFAOYSA-N
InChI=1S/C14H20N2O3/c1-4-16(5-2)10-14(18)19-13-8-6-12(7-9-13)15-11(3)17/h6-9H,4-5,10H2,1-3H3,(H,15,17)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/15367329
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15367329
Propacetamol is a bioprecursor of paracetamol. It is rapidly hydrolyzed by plasma esterases
and releases its constituent paracetamol by the end of its intravenous or intramuscular
administration. Its metabolism is identical to that of paracetamol. It is used in post-operative care and is delivered by I.V. It is given if the patient is unable to take oral or rectally delivered paracetamol and non-steroidal anti-inflammatory drugs are contraindicated. The onset of analgaesia from propacetamol is more rapid than paracetamol given orally. 2 g of propacetamol are equivalent to 1g of paracetamol.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26175881
Curator's Comment: Propacetamol can cross the blood-brain barrier, producing a central analgesic effect.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26157738
Curator's Comment: Intravenous propacetamol (Propacetamol) was produced by Bristol-Myers Squibb, France, in 1985 under the trade name Pro-dafalgan. # Bristol-Myers Squibb
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4794 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27457427 |
|||
Target ID: CHEMBL230 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PRO-DAFALGAN Approved UseSymptomatic treatment of pain:
in surgery, particularly postoperative treatment,
in oncology.
Symptomatic treatment of fever:
in infectious diseases,
in malignant diseases. Launch Date1984 |
|||
Primary | PRO-DAFALGAN Approved UseSymptomatic treatment of pain:
in surgery, particularly postoperative treatment,
in oncology.
Symptomatic treatment of fever:
in infectious diseases,
in malignant diseases. Launch Date1984 |
PubMed
Title | Date | PubMed |
---|---|---|
Plasma and cerebrospinal fluid concentrations of paracetamol after a single intravenous dose of propacetamol. | 1992 Jul |
|
Intravenous ketoprofen in thyroid and parathyroid surgery. | 2001 Apr |
|
Comparative effect of intraoperative propacetamol versus placebo on morphine consumption after elective reduction mammoplasty under remifentanil-based anesthesia: a randomized control trial [ISRCTN71723173]. | 2004 Sep 14 |
|
Intravenous acetaminophen (paracetamol): comparable analgesic efficacy, but better local safety than its prodrug, propacetamol, for postoperative pain after third molar surgery. | 2005 Jul |
|
Onset of acetaminophen analgesia: comparison of oral and intravenous routes after third molar surgery. | 2005 May |
|
Clinical analgesic efficacy and side effects of dexmedetomidine in the early postoperative period after arthroscopic knee surgery. | 2007 Dec |
Sample Use Guides
Method of administration
Intravenous route: Restricted to children weighing 33 kg or more and to adults.
It is recommended to use the product immediately following reconstitution.
Do not mix with other drugs because of the risk of incompatibility.
Children weighing 33 kg or more
Propacetamol is used in infusion over 15 minutes after dilution of the product, using a transfer
device, in 5% glucose solution or 0.9% sodium chloride solution.
In order to comply with blood volume, the maximum volume which may be infused in
children is 1 to 2 ml/kg/injection.
The 1 g powder should be dissolved in a 50 ml flexible bag.
The 2 g powder should be dissolved in a 100 ml flexible bag. Adults
After the product is reconstituted using the transfer device, administration takes place using
5% glucose solution or 0.9% sodium chloride solution (about 100 ml) over 15 minutes.
Posology
In children the posology is 30 mg/kg per injection, i.e. 1.5 ml/kg per injection of the 1 g
solution reconstituted in 50 ml or the 2 g solution reconstituted in 100 ml, to be repeated if
necessary after an interval of at least 6 hours, without exceeding the maximum daily posology
of 120 mg/kg of propacetamol, i.e. 60 mg/kg of paracetamol.
In adults the posology is 1 to 2 g, to be repeated if necessary after an interval of 4 hours,
without exceeding 6 g per day, or in exeptional cases, 8 g per day.
Frequency of administration
Systematic administrations will avoid fluctuations of pain or fever.
In children, they must be given at least 6 hours apart.
In adults, they must be given at least 4 hours apart.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27457427
Curator's Comment: To investigate whether PPCM (Propacetamol) exhibits hTRPV1-activating properties, HEK 293 cells expressing wild type hTRPV1 were examined by standard whole-cell voltage clamp. Measuring ramp currents by 500
ms long depolarizations from -100 to +100 mV, we applied PPCM at increasing concentrations (1 uM to 10 mM).
In hTRPV1-expressing cells 100 uM and higher concentrations activated membrane currents with a strong outward rectification in all cells which also generated capsaicin (1 uM)-induced currents
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN02BE05
Created by
admin on Fri Dec 15 16:14:45 GMT 2023 , Edited by admin on Fri Dec 15 16:14:45 GMT 2023
|
||
|
NCI_THESAURUS |
C2356
Created by
admin on Fri Dec 15 16:14:45 GMT 2023 , Edited by admin on Fri Dec 15 16:14:45 GMT 2023
|
||
|
WHO-ATC |
N02BE05
Created by
admin on Fri Dec 15 16:14:45 GMT 2023 , Edited by admin on Fri Dec 15 16:14:45 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C063776
Created by
admin on Fri Dec 15 16:14:45 GMT 2023 , Edited by admin on Fri Dec 15 16:14:45 GMT 2023
|
PRIMARY | |||
|
C75081
Created by
admin on Fri Dec 15 16:14:45 GMT 2023 , Edited by admin on Fri Dec 15 16:14:45 GMT 2023
|
PRIMARY | |||
|
PROPACETAMOL
Created by
admin on Fri Dec 15 16:14:45 GMT 2023 , Edited by admin on Fri Dec 15 16:14:45 GMT 2023
|
PRIMARY | |||
|
100000081129
Created by
admin on Fri Dec 15 16:14:45 GMT 2023 , Edited by admin on Fri Dec 15 16:14:45 GMT 2023
|
PRIMARY | |||
|
DTXSID3057800
Created by
admin on Fri Dec 15 16:14:45 GMT 2023 , Edited by admin on Fri Dec 15 16:14:45 GMT 2023
|
PRIMARY | |||
|
266-390-1
Created by
admin on Fri Dec 15 16:14:45 GMT 2023 , Edited by admin on Fri Dec 15 16:14:45 GMT 2023
|
PRIMARY | |||
|
5CHW4JMR82
Created by
admin on Fri Dec 15 16:14:45 GMT 2023 , Edited by admin on Fri Dec 15 16:14:45 GMT 2023
|
PRIMARY | |||
|
5400
Created by
admin on Fri Dec 15 16:14:45 GMT 2023 , Edited by admin on Fri Dec 15 16:14:45 GMT 2023
|
PRIMARY | |||
|
2290
Created by
admin on Fri Dec 15 16:14:45 GMT 2023 , Edited by admin on Fri Dec 15 16:14:45 GMT 2023
|
PRIMARY | |||
|
CHEMBL1851805
Created by
admin on Fri Dec 15 16:14:45 GMT 2023 , Edited by admin on Fri Dec 15 16:14:45 GMT 2023
|
PRIMARY | |||
|
DB09288
Created by
admin on Fri Dec 15 16:14:45 GMT 2023 , Edited by admin on Fri Dec 15 16:14:45 GMT 2023
|
PRIMARY | |||
|
68865
Created by
admin on Fri Dec 15 16:14:45 GMT 2023 , Edited by admin on Fri Dec 15 16:14:45 GMT 2023
|
PRIMARY | |||
|
SUB10093MIG
Created by
admin on Fri Dec 15 16:14:45 GMT 2023 , Edited by admin on Fri Dec 15 16:14:45 GMT 2023
|
PRIMARY | |||
|
m9176
Created by
admin on Fri Dec 15 16:14:45 GMT 2023 , Edited by admin on Fri Dec 15 16:14:45 GMT 2023
|
PRIMARY | Merck Index | ||
|
66532-85-2
Created by
admin on Fri Dec 15 16:14:45 GMT 2023 , Edited by admin on Fri Dec 15 16:14:45 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)